Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

- PMLiVE

AZ signs yet another cancer immunotherapy deal

Will work with Omnis to develop viruses that target tumour cells

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

Cyramza gets FDA green light in lung cancer

Drug steadily being approved for further uses

- PMLiVE

Thousands more seek lung cancer tests thanks to campaign

Be Clear on Cancer campaign coincided with 3,000 extra GP referrals

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links